Home/Pipeline/Pulsante for Ischemic Stroke

Pulsante for Ischemic Stroke

Acute Ischemic Stroke

Research/Clinical StudyActive

Key Facts

Indication

Acute Ischemic Stroke

Phase

Research/Clinical Study

Status

Active

Company

Realeve

About Realeve

Realeve is a private, clinical-stage medical device company pioneering a novel, externally powered neuromodulation platform. Its lead product, the Pulsante SPG microstimulation implant, is designed for minimally invasive surgical placement and is activated by a handheld external controller. While initially targeting the severe pain of cluster headaches with documented clinical use, the company is exploring broader CNS applications, including ischemic stroke and blood-brain barrier modulation. Founded in 2019 and based in Cleveland, Ohio, Realeve appears to be in a late-clinical or early commercial stage for its lead indication.

View full company profile

Therapeutic Areas

Neurology Pain Management

Other Acute Ischemic Stroke Drugs

Drug	Company	Phase	Status
Presendin™ (Exenatide)	Invex Therapeutics	Phase 2	Active
Supernova Stent Retriever	Gravity Medical Technology	Commercial	Active
Neutron Reperfusion Catheter	Gravity Medical Technology	Commercial	Active
AST-004	Astrocyte Pharmaceuticals	Phase 1/2	IND cleared March 2024
scp776	Silver Creek Pharmaceuticals	Phase 2	Active
VB-001	VST Bio	Pre-clinical	Active
Pulse NanoMED for AIS	Euphrates Vascular	Pre-clinical	Active
NeVa NET	Vesalio	Development/Commercial	Active
ApTOLL	aptaTargets	Phase 2	Transferred
ThermoSuit® for Acute Ischemic Stroke	Life Recovery Systems HD	Pivotal Trial (Planned)	Active
Glenzocimab (ACT017)	Acticor Biotech	Phase 2/3	Active
eTrieve™ Microcatheter	Magneto Thrombectomy Solutions	Phase 1	Active